NextCell Pharma AB

OM:NXTCL Rapporto sulle azioni

Cap. di mercato: SEK 126.4m

NextCell Pharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mathias Svahn

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOno data
Proprietà del CEO0.7%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazioneNessun dato

Aggiornamenti recenti sulla gestione

Recent updates

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Mar 09
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

Oct 07
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

May 23
NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Feb 01
NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Sep 21
We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31
Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Feb 15
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mathias Svahn rispetto agli utili di NextCell Pharma?
DataCompenso totaleStipendioGuadagni aziendali
Aug 31 2024n/an/a

-SEK 42m

May 31 2024n/an/a

-SEK 37m

Feb 29 2024n/an/a

-SEK 39m

Nov 30 2023n/an/a

-SEK 41m

Aug 31 2023n/an/a

-SEK 40m

May 31 2023n/an/a

-SEK 40m

Feb 28 2023n/an/a

-SEK 38m

Nov 30 2022n/an/a

-SEK 37m

Aug 31 2022n/an/a

-SEK 35m

May 31 2022n/an/a

-SEK 30m

Feb 28 2022n/an/a

-SEK 28m

Nov 30 2021n/an/a

-SEK 26m

Aug 31 2021n/an/a

-SEK 25m

May 31 2021n/an/a

-SEK 25m

Feb 28 2021n/an/a

-SEK 23m

Nov 30 2020n/an/a

-SEK 19m

Aug 31 2020n/an/a

-SEK 18m

May 31 2020n/an/a

-SEK 17m

Feb 29 2020n/an/a

-SEK 17m

Nov 30 2019n/an/a

-SEK 16m

Aug 31 2019SEK 984kSEK 984k

-SEK 18m

May 31 2019n/an/a

-SEK 17m

Feb 28 2019n/an/a

-SEK 15m

Nov 30 2018n/an/a

-SEK 16m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Mathias sia ragionevole rispetto ad aziende di dimensioni simili nel mercato Swedish.

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Mathias con le performance aziendali.

AMMINISTRATORE DELEGATO

Mathias Svahn (48 yo)

no data

Mandato

SEK 983,528

Compensazione

Dr. Mathias Svahn, Ph D is Founder of NextCell Pharma AB(also known as Cellaviva AB) and serves as its Chief Executive Officer. Dr. Svahn was an Executive Director at NextCell Pharma AB.

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Mathias Svahn
Founder & CEOno dataSEK 983.53k0.69%
SEK 877.6k
Patrik Fagerholm
Chief Financial Officer3.2yrsNessun datoNessun dato
Lindsay Davies
Chief Scientific Officer4.4yrsNessun datoNessun dato
Edvard Smith
Medical Director & Directorno dataNessun datoNessun dato
Sofie Jansson
Head of Cellaviva1.6yrsNessun datoNessun dato
Sofia Sisay
Head of Clinical Trials1.6yrsNessun datoNessun dato

2.4yrs

Durata media

46.5yo

Età media

Gestione esperta: Il team dirigenziale di NXTCL è considerato esperto (durata media dell'incarico 2.4 anni).